With two weeks to go until recreational cannabis is legal in Canada, Ottawa-area pot firm Canopy Growth (TSX:WEED)(NYSE:CGC) is deepening its roots in the medicinal market through a new pilot project with the Ontario Long Term Care Association.
The Smiths Falls-based licensed cannabis producer announced Wednesday that its wholly-owned subsidiary, Spectrum Cannabis, will run a pilot with the OLTCA to study the effects of medical-use marijuana in long-term care facilities across Ontario.
The six-month pilot program will explore cannabis-based therapies as an alternative to other therapeutics for pain and cognitive function for residents in a select group of homes. OLTCA will design and implement the program with Canopy supplying the product.
(Sponsored)
How Carleton is using simulation and visualization to improve training, design and human performance
From healthcare to aviation to architecture, simulation and visualization tools have become an essential part of training, analysis and decision-making in sectors that rely on precision. At Carleton University, researchers
Advertising or posting a job opportunity is about to get more complicated for many local organizations with 25 or more employees. That’s because of a slew of updates to Ontario’s
A release calls the pilot one of the first comprehensive studies of cannabis-based therapies in long-term care situations and says as many as 500 participants will take part in the program.
A spokesperson for the OLTCA said that while medical cannabis treatments are prescribed “as appropriate,” it remains an under-researched area. Canopy president and co-CEO Mark Zekulin added that the pilot project hopes to improve consistency for seniors’ quality of life in long-term care homes.
Shares of Canopy Growth were trading around $62 on the TSX Wednesday, an increase of roughly six per cent over the course of the day. The cannabis firm’s share price has nearly doubled since mid-August, but remained flat through September.
